Abnormal Liver Function Tests of Patients With Coronavirus Disease 2019 in Mainland China: A Systematic Review and Meta- Analysis

J Gastrointestin Liver Dis. 2020 Jun 3;29(2):219-226. doi: 10.15403/jgld-2513.

Abstract

Aims: Comparing the risk of abnormal liver function tests between severe and non-severe patients with coronavirus disease 2019 (COVID-19) by meta-analysis.

Methods: A literature search was conducted using the databases PubMed, Embase, and Cochrane Library. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using fixed- or random-effects models. Publication bias was detected by the Harbord test.

Results: We included 8 articles comprising 7,467 COVID-19 patients. When compared between severe and non-severe COVID-19 patients, the pooled ORs of elevated alanine aminotransferase, aspartate aminotransferase, total bilirubin, and lactate dehydrogenase levels were 2.35 (95% CI 1.38-3.98), 3.21 (95% CI 2.59-3.98), 1.87 (95% CI 1.32-2.65), and 4.83 (95% CI 2.90-8.05), respectively.

Conclusions: The severity of COVID-19 is associated with liver damage, and can be a risk factor for abnormal liver function tests.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Betacoronavirus*
  • China
  • Coronavirus Infections / diagnosis
  • Coronavirus Infections / physiopathology*
  • Hepatic Insufficiency / diagnosis
  • Hepatic Insufficiency / virology*
  • Humans
  • Liver Function Tests
  • Pandemics
  • Pneumonia, Viral / diagnosis
  • Pneumonia, Viral / physiopathology*
  • Severity of Illness Index*

Supplementary concepts

  • COVID-19
  • severe acute respiratory syndrome coronavirus 2